Description du projet
Se préparer à répondre aux besoins urgents de la prochaine pandémie
Face à la pandémie de COVID-19, la réponse à la demande élevée de produits et services médicaux s’est révélée insuffisante. Au vu de cette situation, il est nécessaire d’adopter une nouvelle approche pour répondre aux pics de demande en périodes de crises sanitaires. Le projet RESERVIST, financé par l’UE, y remédiera en mettant en place un réseau central de centres de fabrication et de distribution afin de répondre aux besoins urgents en matière d’approvisionnement, et ce, en l’espace de 48 heures. Pour ce faire, il mettra en relation les entreprises pertinentes du secteur, en optimisant la production et la distribution tout en collaborant avec la communauté mondiale des fabricants en vue de répondre à l’accroissement de la demande. L’objectif est de tirer parti des dernières innovations et d’accroître la flexibilité de la production, ce qui permettra d’assurer une livraison en temps voulu des fournitures et des services nécessaires pour la prochaine crise sanitaire.
Objectif
RESERVIST aims to establish ‘reservist cells’ that in times of crises can be activated within 48hrs to switch to manufacturing medical products and services that are spiking in demand. Such a ‘reservist cell’ will consist of (i) a backbone network of core companies for manufacturing and testing; (ii) an extended network for further capacities (eg local provision, packaging, distribution, customization,…); (iii) a digital coordination platform and (iv) a pool of experts from the companies of the network. These cells will become operational in case of an emergency/pandemic but to make economic sense, the same approach of rapid flexibility and adaptability will be used to deal with surging demand in ‘normal circumstances’.
To realise this concept, we will first work on three levels individually: network level, connected manufacturing/digital manufacturing level and technical level, the latter referring to tweaking manufacturing lines, developing required materials and establishing links with testing/certification. Next, we will demonstrate the repurposing of 5 existing manufacturing lines within 48hrs towards manufacturing of ‘textile PPE’ (surgical and respiratory face masks, medical aprons) and ‘respiratory ventilators’ (invasive and non invasive) that comply with necessary testing and certification and proceed with the embedment of the reservist cells at the partners in the network. We will develop blueprints for further take-up and replication of the concept to other sectors. Within the project we will develop two replication demos: ‘disinfection equipment’ and ‘emergency medical equipement’. To support the Cells we will tap into the worldwide maker community and into relevant OITBs and networks.
The consortium is strongly industry-driven, including 4 LE and 7 SMEs coming from 7 EU countries. To maximise impact, we will extend our partner network and our Impact Support Group (18 Support Letters provided at proposal stage).
Champ scientifique
- medical and health scienceshealth scienceshealth care serviceseHealth
- medical and health sciencesclinical medicineemergency medicine
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- engineering and technologymaterials engineeringtextiles
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationstelecommunications networksdata networks
Mots‑clés
Programme(s)
Thème(s)
Appel à propositions
H2020-SC1-PHE-CORONAVIRUS-2020-2
Voir d’autres projets de cet appelSous appel
H2020-SC1-PHE-CORONAVIRUS-2020-2-NMBP
Régime de financement
IA - Innovation actionCoordinateur
1070 BRUXELLES
Belgique
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.